Monopar Therapeutics (MNPR) Operating Leases (2022 - 2025)
Quarterly results put Operating Leases at $154920.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $154920.0 (changed N/A YoY), and the annual figure for FY2025 was $154920.0, changed.
Monopar Therapeutics has reported Operating Leases over the past 2 years, most recently at $154920.0 for Q4 2025.
- Operating Leases reached $154920.0 in Q4 2025 per MNPR's latest filing, up from $70881.0 in the prior quarter.
- Across five years, Operating Leases topped out at $154920.0 in Q4 2025 and bottomed at $8408.0 in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 154,920.00 |
| Sep 30, 2025 | 70,881.00 |
| Jun 30, 2025 | 80,366.00 |
| Dec 31, 2022 | 8,408.00 |
| Sep 30, 2022 | 20,850.00 |
| Jun 30, 2022 | 80,125.00 |
| Mar 31, 2022 | 25,338.00 |